Lake Street Capital Boosts Evaxion A/S (NASDAQ:EVAX) Price Target to $11.00

Evaxion A/S (NASDAQ:EVAX) had its target price lifted by equities researchers at Lake Street Capital from $6.00 to $11.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Lake Street Capital’s price objective suggests a potential upside of 68.45% from the company’s current price.

A number of other equities analysts also recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evaxion A/S in a research report on Tuesday, October 14th. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Evaxion A/S in a research report on Monday. Finally, Wall Street Zen raised Evaxion A/S to a “hold” rating in a report on Friday, June 27th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $13.50.

Evaxion A/S Stock Down 7.9%

Shares of EVAX opened at $6.53 on Monday. Evaxion A/S has a 52 week low of $1.20 and a 52 week high of $15.50. The company has a quick ratio of 3.42, a current ratio of 3.42 and a debt-to-equity ratio of 1.73. The company has a market capitalization of $9.14 million, a price-to-earnings ratio of -4.95 and a beta of 0.23. The stock’s 50-day moving average price is $4.18 and its 200-day moving average price is $2.87.

Evaxion A/S (NASDAQ:EVAX) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.26). The business had revenue of $0.04 million during the quarter. On average, sell-side analysts predict that Evaxion A/S will post -0.15 EPS for the current year.

Institutional Trading of Evaxion A/S

An institutional investor recently bought a new position in Evaxion A/S stock. XTX Topco Ltd bought a new stake in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 16,281 shares of the company’s stock, valued at approximately $30,000. XTX Topco Ltd owned about 1.16% of Evaxion A/S as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 11.04% of the company’s stock.

Evaxion A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.